다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Pharmacological research : the official journal of the Italian Pharmacological Society, v.107, 2016년, pp.1 - 18
Cortese, F. , Gesualdo, M. , Cortese, A. , Carbonara, S. , Devito, F. , Zito, A. , Ricci, G. , Scicchitano, P. , Ciccone, M.M.
AI-Helper
Rosuvastatin is a fully synthetic statin wich acts by interfering with the endogenous synthesis of cholesterol through competitively inhibiting the 3-hydroxy-3-methylglutaryl coenzyme A reductase, a liver enzyme responsible of the rate-limiting step in cholesterol synthesis. When compared to other m...
Atherosclerosis Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) 217 Suppl. 1 S1 2011 ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
Eur. Heart J. Conroy 24 987 2003 10.1016/S0195-668X(03)00114-3 Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project
Lancet Cholesterol Treatment Trialists⿿ (CTT) Collaboration 376 November (9753) 1670 2010 10.1016/S0140-6736(10)61350-5 Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials
J. Am. Coll. Cardiol. Mills 52 November (22) 1769 2008 10.1016/j.jacc.2008.08.039 Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients
N. Engl. J. Med. Shepherd 5 November (16) 1301 1995 10.1056/NEJM199511163332001 Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
Expert Opin. Drug Saf. Davidson 3 November (6) 547 2004 10.1517/14740338.3.6.547 Rosuvastatin safety: lessons from the FDA review and post-approval surveillance
Am. J. Cardiol. Jones 92 July (2) 152 2003 10.1016/S0002-9149(03)00530-7 Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial)
Am. Heart J. Schuster 147 April (4) 705 2004 10.1016/j.ahj.2003.10.004 Effects of switching statins on achievement of lipid goals: measuring effective reductions in cholesterol using rosuvastatin therapy (MERCURY I) study
Am. Heart J. Ballantyne 151 May (5) 2006 Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: measuring effective reductions in cholesterol using rosuvastatin therapy (MERCURY)II
Trials Clearfield 7 December (21) 35 2006 10.1186/1745-6215-7-35 Comparison of the efficacy and safety of rosuvastatin 10⿿mg and atorvastatin 20⿿mg in high-risk patients with hypercholesterolemia⿿prospective study to evaluate the use of low doses of the Statins Atorvastatin and rosuvastatin (PULSAR)
G. Ital. Cardiol. (Rome) Colivicchi 14 April (4) 248 2013 The new AIFA Note 13: critical and contradictory issues
Clin. Interv. Aging Long 6 27 2011 Clinical utility of rosuvastatin and other statins for cardiovascular risk reduction among the elderly
Am. Heart J. Istvan 144 Suppl. 6 S27 2002 10.1067/mhj.2002.130300 Structural mechanism for statin inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase
Cardiovasc. Drug Rev. Olsson 20 4 303 2002 10.1111/j.1527-3466.2002.tb00099.x Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor
J. Clin. Pharmacol. White CM1 42 September (9) 963 2002 10.1177/0091270002042009002 A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin
Br. J. Clin. Pharmacol. Martin 54 November (5) 472 2002 10.1046/j.1365-2125.2002.01688.x Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers
N. Engl. J. Med. Ross 340 January (2) 115 1999 10.1056/NEJM199901143400207 Atherosclerosis⿿an inflammatory disease
J. Am. Coll. Cardiol. Corretti 39 January (2) 257 2002 10.1016/S0735-1097(01)01746-6 Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force
Curr. Med. Res. Opin. Tsiara 19 6 540 2003 10.1185/030079903125002225 Early vascular benefits of statin therapy
Am. J. Ther. Palaniswamy 17 January⿿February (1) 75 2010 10.1097/MJT.0b013e31819cdc86 nisms underlying pleiotropic effects of statins
J. Hum. Hypertens Hughes 10 June (6) 387 1996 The role of isoprenoids in vascular smooth muscle: potential benefits of statins unrelated to cholesterol lowering
J. Geriatr. Cardiol. Sun 9 June (2) 180 2012 Rosuvastatin inhibits the smooth muscle cell proliferation by targeting TNFα mediated Rho kinase pathway
Zhonghua Xin Xue Guan Bing Za Zhi Zhang 33 January (1) 73 2005 The expression of Rho/Rho kinase of cardiac muscle in heart failure rats caused by pressure overload and the intervention of fasudil
Zhonghua Yi Xue Za Zhi Zhang 92 December (48) 3438 2012 [Effects of rho-kinase inhibitor on cardiac hypertrophy of left ventricle in spontaneously hypertensive rats]
Future Cardiol. Surma 7 September (5) 657 2011 10.2217/fca.11.51 Rho kinase as a therapeutic target in cardiovascular disease
Circulation Kalinowski 105 February (8) 933 2002 10.1161/hc0802.104283 Increased nitric oxide bioavailability in endothelial cells contributes to the pleiotropic effect of cerivastatin
J. Biol. Chem. Laufs 273 September (37) 24266 1998 10.1074/jbc.273.37.24266 Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase
Cardiovasc. Drugs Ther. Ito 16 March (2) 121 2002 10.1023/A:1015701415588 HMG-CoA reductase inhibitors reduce interleukin-6 synthesis in human vascular smooth muscle cells
J. Cell. Mol. Med. Loppnow 15 April (4) 994 2011 10.1111/j.1582-4934.2010.01036.x Statins potently reduce the cytokine-mediated IL-6 release in SMC/MNC cocultures
J. Am. Soc. Nephrol. Essig 9 August (8) 1377 1998 10.1681/ASN.V981377 Lovastatin modulates in vivo and in vitro the plasminogen activator/plasmin system of rat proximal tubular cells: role of geranylgeranylation and Rho proteins
Kidney Int. Haslinger 62 November (5) 1611 2002 10.1046/j.1523-1755.2002.00601.x Simvastatin increases fibrinolytic activity in human peritoneal mesothelial cells independent of cholesterol lowering
Hypertension Ikeda 36 September (3) 325 2000 10.1161/01.HYP.36.3.325 Fluvastatin inhibits matrix metalloproteinase-1 expression in human vascular endothelial cells
J. Clin. Pharmacol. Ghirlanda 33 March (3) 226 1993 10.1002/j.1552-4604.1993.tb03948.x Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study
Lancet Moosmann 363 March (9412) 892 2004 10.1016/S0140-6736(04)15739-5 Biochim: selenoprotein synthesis and side-effects of statins
Biophys. Acta Lescure 1790 November (11) 1569 2009 10.1016/j.bbagen.2009.03.002 Selenoprotein function and muscle disease
Can. J. Physiol. Pharmacol. Fedacko 91 Feberuary (2) 165 2013 10.1139/cjpp-2012-0118 Coenzyme Q(10) selenium in statin-associated myopathy treatment
Expert Rev. Cardiovasc. Ther. DiNicolantonio 10 October (10) 1329 2012 10.1586/erc.12.92 CoQ10 and L-carnitine for statin myalgia?
Curr. Med. Res. Opin. Meek 28 March (3) 371 2012 10.1185/03007995.2012.657302 Daily and intermittent rosuvastatin 5mg therapy in statin intolerant patients: an observational study
BMJ Macaulay 345 November (19) e7457 2012 10.1136/bmj.e7457 Once weekly rosuvastatin is useful in statin intolerance
Clin. Lipidol. Kennedy 5 July⿿August (4) 308 2011 10.1016/j.jacl.2011.03.454 acy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance
Verh. K. Acad. Geneeskd. Belg. Holvoet 70 3 193 2008 Relations between metabolic syndrome, oxidative stress and inflammation and cardiovascular disease
Mol. Cell. Endocrinol. Galic 316 March (2) 129 2010 10.1016/j.mce.2009.08.018 Adipose tissue as an endocrine organ
Ann. Intern. Med. Vijan 140 April (8) 650 2004 10.7326/0003-4819-140-8-200404200-00013 Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians
J. Clin. Endocrinol. Metab. Ginsberg 91 February (2) 383 2006 10.1210/jc.2005-2084 Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia
Atherosclerosis Beſtowski 219 December (2) 526 2011 10.1016/j.atherosclerosis.2011.08.009 Opposite effects of pravastatin and atorvastatin on insulin sensitivity in the rat: role of vitamin D metabolites
Eur. J. Med. Chem. Fong 85 October 6 661 2014 10.1016/j.ejmech.2014.08.037 Statins in therapy: understanding their hydrophilicity, lipophilicity, binding to 3-hydroxy-3-methylglutaryl-CoA reductase, ability to cross the blood brain barrier and metabolic stability based on electrostatic molecular orbital studies
Atherosclerosis Beſtowski 219 December (2) 526 2011 10.1016/j.atherosclerosis.2011.08.009 Opposite effects of pravastatin and atorvastatin on insulin sensitivity in the rat: role of vitamin D metabolites
Eur. J. Pharmacol. Mäuser 564 37 2007 10.1016/j.ejphar.2007.02.024 Direct adipotropic actions of atorvastatin: differentiation state-dependent induction of apoptosis, modulation of endocrine function, and inhibition of glucose uptake
Diabetologia Nakata 49 1881 2006 10.1007/s00125-006-0269-5 Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control
J. Biol. Chem. Siddals 279 38353 2004 10.1074/jbc.M404838200 Abrogation of insulin-like growth factor-I (IGF-I) and insulin action by mevalonic acid depletion: synergy between protein prenylation and receptor glycosylation pathways
Nutr. Metab. Cardiovasc. Dis. de las Heras 23 November (11) 1107 2013 10.1016/j.numecd.2012.11.009 Factors involved in rosuvastatin induction of insulin sensitization in rats fed a high fat diet
Diabetol. Metab. Syndr. Neto-Ferreira 5 July (1) 32 2013 10.1186/1758-5996-5-32 Pleiotropic effects of rosuvastatin on the glucose metabolism and the subcutaneous and visceral adipose tissue behavior in C57Bl/6 mice
Atherosclerosis Naples 198 May (1) 94 2008 10.1016/j.atherosclerosis.2007.11.003 Effect of rosuvastatin on insulin sensitivity in an animal model of insulin resistance: evidence for statin-induced hepatic insulin sensitization
Clin. Sci. (Lond.) Fraulob 123 August (4) 259 2012 10.1042/CS20110373 Beneficial effects of rosuvastatin on insulin resistance, adiposity, inflammatory markers and non-alcoholic fatty liver disease in mice fed on a high-fat diet
Clin. Invest. Arterioscler. Valero-Muñoz 26 July⿿August (4) 161 2014 Rosuvastatin improves insulin sensitivity in overweight rats induced by high fat diet. Role of SIRT1 in adipose tissue
Eur. J. Gastroenterol. Hepatol. Maffioli 25 September (9) 1113 2013 10.1097/MEG.0b013e3283608317 Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin
Fundam. Clin. Pharmacol. Schachter 19 February (1) 117 2005 10.1111/j.1472-8206.2004.00299.x Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update
Syst. Rev. Bonsu 2 April 22 2013 10.1186/2046-4053-2-22 Lipophilic versus hydrophilic statin therapy for heart failure: a protocol for an adjusted indirect comparison meta-analysis
N. Engl. J. Med. Kjekshus 357 November (22) 2248 2007 10.1056/NEJMoa0706201 Rosuvastatin in older patients with systolic heart failure
Lancet Gissi-H.F Investigators Tavazzi 372 October (9645) 1231 2008 10.1016/S0140-6736(08)61240-4 Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial
Eur. Heart J. Gullestad 33 September (18) 2290 2012 10.1093/eurheartj/ehs077 Galectin-3 predicts response to statin therapy in the controlled rosuvastatin multinational trial in heart failure (CORONA)
J. Am. Coll. Cardiol. Cleland 54 November (20) 1850 2009 10.1016/j.jacc.2009.06.041
Circ. J. Izawa 79 161 2015 10.1253/circj.CJ-14-0877 Assessment of lipophilic vs: hydrophilic statin therapy in acute myocardial infarction
Korean J. Intern. Med. Kim 26 September (3) 294 2011 10.3904/kjim.2011.26.3.294 Comparison of clinical outcomes of hydrophilic and lipophilic statins in patients with acute myocardial infarction
Circ. J. Sakamoto 71 September (9) 1348 2007 10.1253/circj.71.1348 MUSASHI-AMI Investigators usefulness of hydrophilic vs lipophilic statins after acute myocardial infarction: subanalysis of MUSASHI-AMI
Clin. Exp. Hypertens. Kai 30 October (7) 530 2008 10.1080/10641960802251925 Comparison of the effect of lipophilic and hydrophilic statins on serum adiponectin levels in patients with mild hypertension and dyslipidemia: kinki Adiponectin Interventional (KAI) Study
Int. J. Cardiol. Fujita 129 September (2) 294 2008 10.1016/j.ijcard.2007.06.054 Pleiotropic effects of statins on cardiovascular events in the Japanese Coronary Artery Disease study
Circulation Gao 112 September (12) 1763 2005 10.1161/CIRCULATIONAHA.105.552174 Simvastatin therapy normalizes sympathetic neural control in experimental heart failure: roles of angiotensin II type 1 receptors and NAD(P)H oxidase
Circ. J. Tsutamoto 75 9 2160 2011 10.1253/circj.CJ-11-0222 Effect of atorvastatin vs: rosuvastatin on cardiac sympathetic nerve activity in non-diabetic patients with dilated cardiomyopathy
JAMA Nissen 295 April (13) 1556 2006 10.1001/jama.295.13.jpc60002 Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial
Circulation Ballantyne 19 2458 2008 10.1161/CIRCULATIONAHA.108.773747 Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden
JAMA Crouse 297 March (12) 1344 2007 10.1001/jama.297.12.1344 Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals withsubclinical atherosclerosis: the METEOR Trial
Am. Heart J. Underhill 155 March (3) 2008 Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderatelyhypercholesterolemic patients: a high-resolution magnetic resonance imaging trial
N. Engl. J. Med. Ridker 359 November (21) 2195 2008 10.1056/NEJMoa0807646 Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein
J. Am. Coll. Cardiol. O'Keefe 43 June (11) 2142 2004 10.1016/j.jacc.2004.03.046 Optimal low-density lipoprotein is 50 to 70mg/dl: lower is better and physiologically normal
J. Am. Coll. Cardiol. Lee 58 October (16) 1664 2011 10.1016/j.jacc.2011.05.057 Benefit of early statin therapy in patients with acute myocardial infarction who have extremely low low-density lipoprotein cholesterol
Atherosclerosis Galle 185 April (2) 219 2006 10.1016/j.atherosclerosis.2005.10.005 Impact of oxidized low density lipoprotein on vascular cells
Biochem. Biophys. Res. Commun. Landsberger 336 November (4) 1005 2005 10.1016/j.bbrc.2005.08.225 Blockade of geranylgeranylation by rosuvastatin upregulates eNOS expression in human venous endothelial cells
Microvasc. Res. Ott 84 July (1) 60 2012 10.1016/j.mvr.2012.03.007 Rosuvastatin improves pulse wave reflection by restoring endothelial function
J. Int. Med. Res. Liu 39 6 2314 2011 10.1177/147323001103900630 Effects of rosuvastatin versus atorvastatin on rho-associated coiled-coil containing protein kinase activity and endothelial function in patients with atherosclerosis
Br. J. Pharmacol. Stalker 133 June (3) 406 2001 10.1038/sj.bjp.0704070 A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid
Angiology Bostan 66 February (2) 122 2015 10.1177/0003319714522107 Beneficial effects of rosuvastatin treatment in patients with metabolic syndrome
Br. J. Diabetes Vasc. Dis. Paul 10 6 292 2010 10.1177/1474651410388057 Rosuvastatin treatment is associated with a decrease of serum oxidised low-density lipoprotein/beta2-glycoprotein I complex concentration in type 2 diabetes
Rheumatology (Oxford) Choy June (6) 2014 Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment
J. Exp. Integr. Med. Mikhael 3 2 127 2013 10.5455/jeim.170413.or.065 Effect of rosuvastatin as adjuvant therapy to methotrexate on hematological parameters in patients with moderately-highly active rheumatoid arthritis
Arthritis Res. Ther. Timár 15 5 R105 2013 10.1186/ar4285 Rosuvastatin improves impaired endothelial function, lowers high sensitivity CRP, complement and immuncomplex production in patients with systemic sclerosis⿿a prospective case-series study
J. Neurosurg. Sánchez-Aguilar 118 March (3) 669 2013 10.3171/2012.12.JNS121084 Effect of rosuvastatin on cytokines after traumatic head injury
Curr. Opin. Cardiol. Fauchier 28 January (1) 7 2013 10.1097/HCO.0b013e32835b0956 Statin therapy and atrial fibrillation: systematic review and updated meta-analysis of published randomized controlled trials
Eur. Heart J. Peña 33 February (4) 531 2012 10.1093/eurheartj/ehr460 High-sensitivity C-reactive protein, statin therapy, and risks of atrial fibrillation: an exploratory analysis of the JUPITER trial
Pacing Clin. Electrophysiol. Xia 32 December (12) 1562 2009 10.1111/j.1540-8159.2009.02554.x Effects of rosuvastatin on asymmetric dimethylarginine levels and early atrial fibrillation recurrence after electrical cardioversion
Eur. Heart J. Maggioni 30 October (19) 2327 2009 10.1093/eurheartj/ehp357 Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial
Europace Camm 14 October (10) 1385 2012 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation-developed with the special contribution of the European Heart Rhythm Association
Hepatology Chalasani 55 June (6) 2005 2012 10.1002/hep.25762 The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
Diabetes Care Targher 30 2119 2007 10.2337/dc07-0349 Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients
Eur. Heart J. European Association for Cardiovascular Prevention 32 July (14) 1769 2011
Lancet Athyros 376 December (9756) 1916 2010 10.1016/S0140-6736(10)61272-X
Liver Int. Okada 33 February (2) 301 2013 10.1111/liv.12033 Rosuvastatin ameliorates high-fat and high-cholesterol diet-induced nonalcoholic steatohepatitis in rats
Atherosclerosis Antonopoulos 184 January (1) 233 2006 10.1016/j.atherosclerosis.2005.08.021 Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients
Hepatol. Res. Nakahara 42 November (11) 1065 2012 10.1111/j.1872-034X.2012.01034.x Efficacy of rosuvastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: an open-label, pilot study
Lik. Sprava Skrypnyk May⿿June (5⿿6) 113 2014 ization of long-term treatment with rosuvastatin of patients with myocardial infarction in combination with non-alcoholic steatohepatitis
Curr. Vasc. Pharmacol. Kargiotis 12 May (3) 505 2014 10.2174/15701611113119990009 Effect of rosuvastatin on non-alcoholic steatohepatitis in patients with metabolic syndrome and hypercholesterolaemia: a preliminary report
World J. Gastroenterol. Kargiotis 21 July (25) 7860 2015 10.3748/wjg.v21.i25.7860 Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome
Am. J. Cardiol. Sun 114 October (8) 1234 2014 10.1016/j.amjcard.2014.07.046 Effect of rosuvastatin on coronary flow reserve in patients with systemic hypertension
Int. J. Cardiol. Yun 137 November (3) 246 2009 10.1016/j.ijcard.2008.06.055 The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome
Cardiovasc. Drugs Ther. Cay 24 February (1) 41 2010 10.1007/s10557-010-6224-1 Prevention of peri-procedural myocardial injury using a single high loading dose of rosuvastatin
J. Cardiovasc. Pharmacol. Ther. Wang 18 July (4) 327 2013 10.1177/1074248412474346 Effect of a single high loading dose of rosuvastatin on percutaneous coronary intervention for acute coronary syndromes
Int. J. Cardiol. Yun 146 January (1) 68 2011 10.1016/j.ijcard.2010.04.052 12-month follow-up results of high dose rosuvastatin loading before percutaneous coronary intervention in patients with acute coronary syndrome
J. Am. Coll. Cardiol. Leoncini 63 January (1) 71 2014 10.1016/j.jacc.2013.04.105
J. Am. Coll. Cardiol. Moura 49 February (5) 554 2007 10.1016/j.jacc.2006.07.072 Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis
J. Heart Valve Dis. Moura 21 July (4) 463 2012 Rosuvastatin slows the development of diastolic dysfunction in calcific aortic stenosis
Circulation Eto 105 April (15) 1756 2002 10.1161/01.CIR.0000015465.73933.3B Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways
Blood Coagul. Fibrin. Shi 14 September (6) 575 2003 10.1097/00001721-200309000-00010 Statins increase thrombomodulin expression and function in human endothelial cells by a nitric oxide-dependent mechanism and counteract tumor necrosis factor alpha-induced thrombomodulin downregulation
N. Engl. J. Med. Glynn 360 April (18) 1851 2009 10.1056/NEJMoa0900241 A randomized trial of rosuvastatin in the prevention of venous thromboembolism
Hypertension Strazzullo 49 April (4) 792 2007 10.1161/01.HYP.0000259737.43916.42 Do statins reduce blood pressure?: a meta-analysis of randomized, controlled trials
Int. J. Cardiol. Banach 168 October (3) 2816 2013 10.1016/j.ijcard.2013.03.068 The effects of statins on blood pressure in normotensive or hypertensive subjects⿿a meta-analysis of randomized controlled trial
Hypertens. Res. Li 34 July (7) 869 2011 10.1038/hr.2011.44 Rosuvastatin attenuates the elevation in blood pressure induced by overexpression of human C-reactive protein
Am. J. Physiol. Heart Circ. Physiol. DeMarco 297 September (3) 2009 Rosuvastatin ameliorates the development of pulmonary arterial hypertension in the transgenic(mRen2) 27 rat
Am. J. Physiol. Heart Circ. Physiol. Sun 294 February (2) 2008 Rosuvastatin provides pleiotropic protection against pulmonary hypertension, right ventricular hypertrophy, and coronary endothelial dysfunction in rats
Circulation Foody 113 February (8) 1086 2006 10.1161/CIRCULATIONAHA.105.591446 Statins and mortality among elderly patients hospitalized with heart failure
J. Am. Coll. Cardiol. Sola 47 January (2) 332 2006 10.1016/j.jacc.2005.06.088 Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure
Exp. Rev. Cardiovasc. Ther. Marchioli 7 July (7) 735 2009 10.1586/erc.09.70 Effect of n-3 polyunsaturated fatty acids and rosuvastatin in patients with heart failure: results of the GISSI-HF trial
Eur. J. Heart Fail. Gastelurrutia 15 June (6) 708 2013 10.1093/eurjhf/hft043 Statins in heart failure: not yet the end of the story?
Circulation McMurray 120 December (22) 2188 2009 10.1161/CIRCULATIONAHA.109.849117 Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis
J. Am. Coll. Cardiol. Tang 49 June (24) 2364 2007 10.1016/j.jacc.2007.02.053 Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure
Atherosclerosis Andreou 210 May (1) 194 2010 10.1016/j.atherosclerosis.2009.10.046 Effects of rosuvastatin on myeloperoxidase levels in patients with chronic heart failure: a randomized placebo-controlled study
Eur. Heart J. Gullestad 33 September (18) 2290 2012 10.1093/eurheartj/ehs077 Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)
Eur. J. Heart Fail. Latini 14 September (9) 992 2012 10.1093/eurjhf/hfs092 Investigators of the controlled rosuvastatin multinational trial in heart failure (CORONA) and GISSI-heart failure (GISSI-HF) trials. Pentraxin-3 in chronic heart failure: the CORONA and GISSI-HF trials
N. Engl. J. Med. Fellström 360 April (14) 1395 2009 10.1056/NEJMoa0810177 Rosuvastatin and cardiovascular events in patients undergoing hemodialysis
Nephrology (Carlton) Shah 13 December (8) 667 2008 10.1111/j.1440-1797.2008.00982.x Are traditional risk factors valid for assessing cardiovascular risk in end-stage renal failure patients?
J. Am. Soc. Nephrol. Holdaas 22 July (7) 1335 2011 10.1681/ASN.2010090987 Rosuvastatin in diabetic hemodialysis patients
Int. J. Cardiol. Savarese 167 September (6) 2482 2013 10.1016/j.ijcard.2012.05.010 Effects of atorvastatin and rosuvastatin on renal function: a meta-analysis
Wilmington 2016 Prescribing Information for CRESTOR
Am. J. Cardiol. Cannon 102 December (12A) 5L 2008 10.1016/j.amjcard.2008.09.067 Mixed dyslipidemia, metabolic syndrome, diabetes mellitus, and cardiovascular disease: clinical implications
Lancet Colhoun 64 August (9435) 685 1762 Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
Nutr. Metab. Cardiovasc. Dis. Monesi 24 March (3) 263 2014 10.1016/j.numecd.2013.08.005 Elevated risk of death and major cardiovascular events in subjects with newly diagnosed diabetes: findings from an administrative database
Cardiovasc. Ther. Kawashiri 31 December (6) 335 2013 10.1111/1755-5922.12027
Ann. Intern. Med. Sniderman 135 September (6) 447 2001 10.7326/0003-4819-135-6-200109180-00014 Hypertriglyceridemic hyperapob: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus
J. Int. Med. Res. Katabami 42 April (2) 457 2014 10.1177/0300060513507648 Efficacy of low-dose rosuvastatin in patients with type 2 diabetes and hypo high-density lipoprotein cholesterolaemia
J. Assoc. Phys. India Shah 61 October (10) 732 2013 Efficacy of rosuvastatin in achieving target HDL LDL, triglycerides and total cholesterol levels in type 2 diabetes mellitus (T2DM) with newly diagnosed dyslipidaemia: an open label, nonrandomised, non-interventional and observational study in India
Diabetes Obes. Metab. Stender 7 July (4) 430 2015 Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial
Cardiovasc. Diabetol. Berne 4 June (3) 7 2005 10.1186/1475-2840-4-7 Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study
J. Intern. Med. Wolffenbuttel 257 June (6) 531 2005 10.1111/j.1365-2796.2005.01499.x Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes⿿CORALL study
Diabet. Med. Simsek 29 May (5) 628 2012 10.1111/j.1464-5491.2011.03553.x Effects of rosuvastatin and atorvastatin on glycaemic control in Type 2 diabetes⿿the CORALL study
Am. J. Cardiol. Betteridge 100 October (8) 1245 2007 10.1016/j.amjcard.2007.05.044 Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2mg/L) and low-density lipoprotein cholesterol (<70mg/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study)
ISRN Pharmacol. Barakat 2013 146579 2013 10.1155/2013/146579 Comparison of efficacy and safety of rosuvastatin, atorvastatin and pravastatin among dyslipidemic diabetic patients
J. Prim. Care Community Health Bener 5 February (3) 180 2014 10.1177/2150131914520991 Comparison of cost-effectiveness, safety, and efficacy of rosuvastatin versus atorvastatin, pravastatin, and simvastatin in dyslipidemic diabetic patients with or without metabolic syndrome
Diabetes Care Stegman 37 November (11) 3114 2014 10.2337/dc14-1121 High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: insights from SATURN
Diabetes Metab. Syndr. Obes. Hernández-Ojeda 4 September (7) 401 2014 Effect of rosuvastatin on diabetic polyneuropathy: a randomized, double-blind, placebo-controlled Phase IIa study
J. Vasc. Surg. Sohn 58 Dec (6) 1578 2013 10.1016/j.jvs.2013.06.069 Statin use and lower extremity amputation risk in nonelderly diabetic patients
J. Diabetes Tierney 5 June (2) 207 2013 10.1111/1753-0407.12013 Association of statin use with peripheral neuropathy in the U.S. population 40 years of age or older
Somatosens. Mot. Res. West 31 June (2) 57 2014 10.3109/08990220.2013.840281 Statin use and peripheral sensory perception: a pilot study
Diabetes Care Rajpathak 32 October (10) 1924 2009 10.2337/dc09-0738 Statin therapy and risk of developing type 2 diabetes: a meta-analysis
QJM Mills 104 February (2) 109 2011 10.1093/qjmed/hcq165 Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials
Endocrinology Xia 149 October (10) 5136 2008 10.1210/en.2008-0161 Inhibition of cholesterol biosynthesis impairs insulin secretion and voltage-gated calcium channel function in pancreatic beta-cells
J. Atheroscler. Thromb. Mabuchi 12 2 111 2005 10.5551/jat.12.111 Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients
Diabetologia Nakata 49 August (8) 1881 2006 10.1007/s00125-006-0269-5 Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control
J. Pathol. Draeger 210 September (1) 94 2006 10.1002/path.2018 Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia
Lancet Sattar 375 February (9716) 735 2010 10.1016/S0140-6736(09)61965-6 Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials
Arch. Intern. Med. Culver 172 January (2) 144 2012 10.1001/archinternmed.2011.625 Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative
Lancet Ridker 380 August (9841) 565 2012 10.1016/S0140-6736(12)61190-8 Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial
Am. J. Cardiol. Everett 114 December (11) 1682 2014 10.1016/j.amjcard.2014.08.041 Safety profile of subjects treated to very low low-density lipoprotein cholesterol levels (<30mg/dl) with rosuvastatin 20mg daily (from JUPITER)
J. Am. Coll. Cardiol. Waters 61 January (2) 148 2013 10.1016/j.jacc.2012.09.042 Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes
Biomed. Pharmacother. Güçlü 58 December (10) 614 2004 10.1016/j.biopha.2004.09.005 Effects of a statin group drug, pravastatin, on the insulin resistance in patients with metabolic syndrome
Atherosclerosis Sugiyama 194 October (2) e43 2007 10.1016/j.atherosclerosis.2006.08.023 Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease
Atherosclerosis Koh 204 June (2) 483 2009 10.1016/j.atherosclerosis.2008.09.021 Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients
Int. J. Cardiol. Koh 166 June (2) 509 2013 10.1016/j.ijcard.2011.11.028 Differential metabolic effects of rosuvastatin and pravastatin in hypercholesterolemic patients
BMJ Carter 346 May 23 f2610 2013 10.1136/bmj.f2610 Risk of incident diabetes among patients treated with statins: population based study
Am. J. Cardiol. Navarese 111 April (8) 1123 2013 10.1016/j.amjcard.2012.12.037 Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus
JAMA Preiss 305 June (24) 2556 2011 10.1001/jama.2011.860 Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis
Metabolism Cho 28 2014 Risk of diabetes in patients treated with HMG-CoA reductase inhibitors
Am. J. Cardiol. Shepherd 94 October (7) 882 2004 10.1016/j.amjcard.2004.06.049 Safety of rosuvastatin
Clin. Ther. Glueck 28 June (6) 933 2006 10.1016/j.clinthera.2006.06.004 Rosuvastatin 5 and 10mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies
Am. Heart J. Schwartz 148 July (1) e4 2004 Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial
Clin. Pharmacol. Ther. Schneck 75 May (5) 455 2004 10.1016/j.clpt.2003.12.014 The effect of gemfibrozil on the pharmacokinetics of rosuvastatin
Clin. Pharmacol. Ther. Neuvonen 80 December (6) 565 2006 10.1016/j.clpt.2006.09.003 Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance
Am. J. Health. Syst. Pharm. Merz 64 September (17) 1818 2007 10.2146/ajhp060305 Elevated serum transaminase levels resulting from concomitant use of rosuvastatin and amiodarone
Am. J. Cardiovasc. Drugs Kostapanos 10 1 11 2010 10.2165/13168600-000000000-00000 Rosuvastatin-associated adverse effects and drug⿿drug interactions in the clinical setting of dyslipidemia
Cardiology Vidt 102 1 52 2004 10.1159/000077704 Rosuvastatin-induced arrest in progression of renal disease
Drug Discov. Today Tiwari 11 May (9⿿10) 458 2006 10.1016/j.drudis.2006.03.017 An overview of statin-associated proteinuria
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.